In addition, LL1, as a new STAT3 inhibitor, increases the sensitivity of gefitinib in vitro and in vivo, suggesting that gefitinib combined with STAT3 inhibitors may be considered as an alternative strategy for the treatment of NSCLC patients with acquired resistance to gefitinib. Here, STAT3 is linked to non-small cell lung carcinoma.